Insmed announces FDA acceptance for filing of NDA for ALIS in NTM lung disease
Insmed announced the FDA has notified the company that the NDA for ALIS (Amikacin Liposome Inhalation Suspension) for adult patients with nontuberculous mycobacterial ung disease caused by Mycobacterium avium complex has been accepted and will be considered filed on May 27, 2018. May 16, 2018